Abiopharma

🔍 McGroarty Ryan (Executive)

Company: LifeStance Health Group, Inc. (LFST)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 127,878 shares of Common Stock (Direct)
  Date: 2026-03-09 | Code: A | equity_swap_involved: false | shares_owned_after: 855,489.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 50,929 shares of Common Stock at $6.91 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: false | shares_owned_after: 804,560.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 65,168 shares of Common Stock (Direct)
  Date: 2026-03-09 | Code: A | equity_swap_involved: false | shares_owned_after: 869,728.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 25,644 shares of Common Stock at $6.91 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: false | shares_owned_after: 844,084.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person on March 17, 2025, which vested on March 9, 2026.
• F2: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of PSUs that vested on March 9, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested PSUs and do not constitute any open-market sale.
• F3: Represents PSUs previously granted to the Reporting Person on March 24, 2025, which vested on March 9, 2026.
• F4: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of PSUs that vested on March 9, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested PSUs and do not constitute any open-market sale.
• REMARKS: Chief Financial Officer and Treasurer